Andrew, Thanks so much for you kind response. If there is anything I've learned on this long road to approval for DCVax it's just how very, very complex and detailed the process has been and continues to be. I never imagined how many obstacles NWBO management would have to literally overcome, including to improve, expand, invent, and urge others to create and invent, in order to get us where we are today. Not to mention taking governments by the hand to push through the legislation that would allow us to be approved! I never imagined their workload would include improving and expanding leukapherasis in an entire country, urging others to invent a devise that would manufacture DCs in a closed system...then buying that closed system and expand on it. I didn't know how much of an obstacle quality control would be and that we had to work it into the EDEN system in order to take hours and hours off the completion of one batch of vaccine for one patient! Or push for an auto system to document every step of the creation of the DCVax vaccine and then "discover" the Bosch Matrix, as you've named it, to add the proper adjuvants to each patient's DCVax treatment, in order to make it a personalized cure, not just a manageable disease for, hopefully, each and every patient.
Andrew, you and others have opened our eyes to what's possibly going on beyond the silent front. It's far more than anything I could have imagined, including the possibility that other clinical trials with a DCVax-similar product conducted by other hospital and clinical research centers, may already have confirmed the curative powers of DCVax in other cancers through their research. Please continue to research and write! It's great having a doctor's view of this treatment. And if a few of your projections turn out to be incorrect, no problem. Many of them will be right on target. And I guarantee your contributions have helped many of us longs hold and even expand our shares count through this long, dry period before the light of approval (IMO) fiinally shines through.
Bullish
AI
Market Data 
Markets 
